Literature DB >> 21993183

Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature.

Fade Mahmoud1, Rajesh R Tampi.   

Abstract

BACKGROUND: Valproic acid (VPA) is commonly used to treat many psychiatric conditions in the elderly. VPA-induced parkinsonism is a less common but important adverse effect of this drug.
OBJECTIVES: The purpose of our study was to conduct a literature review to assess VPA-induced parkinsonism in the elderly.
METHODS: We searched Ovid Medline, PubMed, and Cochrane Database (January 1970 to December 2010) using the key words divalproate, divalproex sodium, valproate, depakote, valproic acid, elderly, aged, Parkinson's disease, and parkinsonism. The Naranjo algorithm was used to assess whether a change in clinical status was the result of an adverse drug reaction.
RESULTS: We identified 13 case reports. Available evidence indicated that there was a variable time interval for the development of parkinsonism after VPA therapy. Most cases showed improvement with the withdrawal of the drug, but the rate and extent of improvement was unpredictable. The calculated Naranjo adverse drug reaction scores, for most cases, were between 5 and 6, meaning it was probable that parkinsonism was due to VPA therapy.
CONCLUSIONS: High clinical awareness is required in diagnosing VPA-induced parkinsonism in the elderly due the presence of comorbid neurodegenerative conditions and the usage of antipsychotics in these patients.
Copyright © 2011 Elsevier HS Journals, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993183     DOI: 10.1016/j.amjopharm.2011.09.002

Source DB:  PubMed          Journal:  Am J Geriatr Pharmacother        ISSN: 1876-7761


  12 in total

1.  Drug-induced parkinsonism: A case report.

Authors:  Brianna D Morabito; Barbara Paulison
Journal:  Ment Health Clin       Date:  2018-03-23

Review 2.  Drug Safety in Episodic Migraine Management in Adults. Part 2: Preventive Treatments.

Authors:  Abigail L Chua; Sandhya Mehla; Yulia Y Orlova
Journal:  Curr Pain Headache Rep       Date:  2022-05-19

3.  Can Valproic Acid Regulate Neurogenesis from Nestin+ Cells in the Adult Midbrain?

Authors:  Parisa Farzanehfar; Malcolm K Horne; Tim D Aumann
Journal:  Neurochem Res       Date:  2017-04-22       Impact factor: 3.996

4.  Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.

Authors:  Ashok Sriram; Herbert E Ward; Anhar Hassan; Sanjay Iyer; Kelly D Foote; Ramon L Rodriguez; Nikolaus R McFarland; Michael S Okun
Journal:  J Neurol       Date:  2012-09-25       Impact factor: 4.849

Review 5.  Valproate-Associated Parkinsonism: A Critical Review of the Literature.

Authors:  Florian Brugger; Kailash P Bhatia; Frank M C Besag
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

6.  Non-hyperammonaemic valproate encephalopathy after 20 years of treatment.

Authors:  Elizabeth Caruana Galizia; Jeremy D Isaacs; Hannah R Cock
Journal:  Epilepsy Behav Case Rep       Date:  2017-04-21

7.  Von Economo's disease and postencephalitic parkinsonism responsive to carbidopa and levodopa.

Authors:  Daniel Y Bigman; Bradford D Bobrin
Journal:  Neuropsychiatr Dis Treat       Date:  2018-04-04       Impact factor: 2.570

Review 8.  Parkinsonism: A Rare Adverse Effect of Valproic Acid.

Authors:  Abilash Muralidharan; Jawaria Rahman; Dipanjan Banerjee; Abdul Rub Hakim Mohammed; Bilal Haider Malik
Journal:  Cureus       Date:  2020-06-23

9.  Incidence and Prevalence of Antiepileptic Medication Use in Community-Dwelling Persons with and without Alzheimer's Disease.

Authors:  Tatyana Sarycheva; Heidi Taipale; Piia Lavikainen; Jari Tiihonen; Antti Tanskanen; Sirpa Hartikainen; Anna-Maija Tolppanen
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

10.  Chemical Genetics Screen Identifies Epigenetic Mechanisms Involved in Dopaminergic and Noradrenergic Neurogenesis in Zebrafish.

Authors:  Markus Westphal; Pooja Sant; Alexander-Thomas Hauser; Manfred Jung; Wolfgang Driever
Journal:  Front Genet       Date:  2020-02-25       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.